Vanderbilt-Ingram Cancer Center (VICC) is leading a Phase 3 global trial of a cancer therapy that was initially tested and validated in a VICC research laboratory. One of the first patients treated with the therapy came to VICC after a bump on the head led to an unexpected cancer diagnosis.

For breast cancer prevention, a new study provides evidence for lifestyle modification to reduce weight gain in adults.

Vanderbilt University Medical Center is the world’s first site to treat a patient in the TULSA-PRO Ablation Clinical Trial (TACT), which employs an emerging therapy that uses MRI guidance and robotically driven therapeutic ultrasound to obtain precise prostate cancer tissue ablation.

Jonathan Lehman, M.D., Ph.D., instructor in Medicine in the Division of Hematology/Oncology, has received a Career Development Award from LUNGevity, a nonprofit organization that provides support programs for lung cancer patients and families, public education and funding for innovative scientific research.

Lymphedema research conducted at Vanderbilt University Medical Center (VUMC) to better understand patient risk for this chronic condition and treatment responses received recognition at an international conference.

Fall fashions for women will be on display during the 4th Annual Chic Awearness Fashion Show promoting ovarian cancer awareness and research. The event, to be held Monday, Sept. 26, 6:30 to 8:30 p.m., will benefit the T.J. Martell Foundation, which supports ovarian cancer research at Vanderbilt-Ingram Cancer Center (VICC).

Modulation of T cell metabolism thus may represent a new therapeutic avenue for leukemia patients.